Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study
Liver International · 2026
DOI: 10.1111/liv.70843 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Hazem Abosheaishaa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Queens, New York, USA. Hauptthemen laut MEDLINE: Hypertension, Portal, Adrenergic beta-Antagonists, Liver Cirrhosis, Portal Vein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Portal vein thrombosis (PVT) is a significant complication of cirrhosis. Nonselective beta‐blockers (NSBBs) are standard therapy for portal hypertension, but their effect on PVT risk remains uncertain.
Aim
To assess whether NSBB use after variceal band ligation increases PVT risk and to compare outcomes among propranolol, carvedilol and no NSBB therapy.
Methods
We conducted a retrospective cohort study using the TriNetX US Collaborative Network (> 110 million patients). Adults with cirrhosis and portal hypertension who underwent variceal band ligation (2010–2024) were included. Patients were stratified by NSBB exposure and matched 1:1 on 12 clinical variables. The primary outcome was incident PVT; secondary outcome was all‐cause mortality. Kaplan–Meier analysis evaluated time‐to‐event outcomes.
Results
After matching ( n = 4296 per group), NSBB use was associated with higher PVT incidence compared with no NSBBs (9.5% vs. 5.4%; RR 1.765, 95% CI 1.500–2.077). Propranolol was associated with increased PVT risk, whereas carvedilol showed similar PVT incidence to controls and significantly lower mortality compared with both propranolol and no NSBB use.
Conclusions
Propranolol use was linked to increased PVT risk, while carvedilol did not elevate PVT risk and was associated with improved survival. Beta‐blocker selection may meaningfully influence outcomes in cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, Queens, New York, USA.
- Department of Gastroenterology, West Virginia University, Morgantown, West Virginia, USA.
- Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
- Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic-Florida, Weston, USA.
- Faculty of Medicine, Menoufia University, Menoufia Governorate, Shebin El-Kom, Egypt.
- Department of Gastroenterology and Hepatology, Maadi Armed Forces Medical Complex, Military Medical Academy, Cairo, Egypt.
ORCID-Profile: Hazem Abosheaishaa, Khaled Elfert, Mohammed Abusuliman, Abdellatif Ismail, Abdullah Olimy, Ahmed Elsayed Alzamzamy, Ahmed Omran, Vincent Rizzo, Mahmoud Nassar, Mohamed El-Kassas
Zitieren
APA
Abosheaishaa, H., Elfert, K., Abusuliman, M., Ismail, A., Olimy, A., Alzamzamy, A. E., Omran, A., Rizzo, V., Nassar, M., & El-Kassas, M. (2026). Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study. Liver International. https://doi.org/10.1111/liv.70843
Vancouver
Abosheaishaa H, Elfert K, Abusuliman M, Ismail A, Olimy A, Alzamzamy AE, et al. Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study. Liver International. 2026. doi:10.1111/liv.70843
BibTeX
@article{Abosheaishaa2026,
author = {Abosheaishaa, Hazem and Elfert, Khaled and Abusuliman, Mohammed and Ismail, Abdellatif and Olimy, Abdullah and Alzamzamy, Ahmed Elsayed and Omran, Ahmed and Rizzo, Vincent and Nassar, Mahmoud and El-Kassas, Mohamed},
title = {Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta‐Blockers: A Multi‐Institutional Cohort Study},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70843}
}
EUVIMED